ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.
The Company is also in the final stages of achieving FDA approval for Re-Tain™, a bacteriocin-based product to treat subclinical mastitis in lactating cows without the use of traditional human antibiotics. Mastitis infections result in approximately $2 BILLION in economic losses to the U.S. dairy industry annually. Reducing the use of antibiotics in the human food chain is a national imperative.
Our Core Technology
CEO Michael Brigham discusses ImmuCell’s core technology with Dr. Joseph H. Crabb former Chief Scientific Officer and VP of Product Development for ImmuCell and the developer of First Defense.
ImmuCell at the Lytham Partners Fall 2022 Investor Conference*
Wednesday September 28, 2022
*A comment made by Mr. Brigham during the recent Lytham Partners 2022 Fall Conference presentation incorrectly referred to the potential FDA approval date for Re-Tain being in the second half of 2024, instead of the second half of 2023, as consistently disclosed in all other public disclosures. Please take note at time signatures 30:21 and 30:35 as you listen to the playback of this presentation. The potential FDA approval date for Re-Tain is the second half of 2023, not 2024.
11-22-22 – Third Quarter Fiscal Year 2022 Conference Call
08-12-22 – Second Quarter Fiscal Year 2022 Conference Call
05-13-22 – First Quarter Fiscal Year 2022 Conference Call
02-23-22 – Fourth Quarter and Fiscal Year 2021 Conference Call
11-16-21 – Third Quarter Fiscal Year 2021 Conference Call
08-13-21 – Second Quarter Fiscal Year 2021 Conference Call
05-14-21 – First Quarter Fiscal Year 2021 Conference Call